Merck reported its sac-TMT antibody-drug conjugate achieved a first global Phase 3 win ahead of schedule, marking a milestone for the company’s late-stage pipeline. The candidate, developed with China-based Kelun-Biotech, succeeded in a global Phase 3 study, strengthening Merck’s position as it navigates upcoming patent expirations. Separately, Merck said an ADC licensed from China hit a key mark in its first major global trial for endometrial cancer. The program is the first in a broader set of late-stage studies supporting Merck’s ambition to expand ADC revenue in the coming decade.